Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP:ALPMY)

13.56 +0.48 (+3.67%)
Streaming Delayed Price Updated: 2:48 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma Inc

< Previous 1 2 3 Next >
News headline image
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan ↗
Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
News headline image
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold ↗
Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
News headline image
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial ↗
Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in... 
Via Benzinga
News headline image
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat ↗
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
News headline image
Here's What Recent News From the FDA Means for AstraZeneca ↗
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Via The Motley Fool
News headline image
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial ↗
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease... 
Via Benzinga
News headline image
The IPO Recap – Party Is Everything But Over ↗
Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled IPOs, marking the fifth week in 2021 with... 
Via Benzinga
Topics Initial Public Offering
News headline image
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer ↗
The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
The 2 Best Pharma Stocks to Buy on Dips ↗
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Via Talk Markets
News headline image
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-... 
Via Benzinga
News headline image
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics ↗
Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and... 
Via Benzinga
Topics Regulatory Compliance
News headline image
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold ↗
In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of... 
Via Benzinga
News headline image
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat ↗
FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company’s anemia treatment in chronic kidney... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.